Skip to content

Research at St Andrews

Risk factors associated with biochemically detected and hospitalised acute kidney injury in patients prescribed renin angiotensin system inhibitors

Research output: Contribution to journalArticlepeer-review

DOI

Open Access permissions

Open

Author(s)

Patrick B Mark, Richard Papworth, Nitish Ramparsad, Laurie A Tomlinson, Simon Sahwney, Corri Black, Alex McConnachie, Colin McCowan

School/Research organisations

Abstract

Aims Therapy with angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) is a mainstay of treatment for heart failure (HF), diabetes mellitus (DM) and chronic kidney disease (CKD). These agents have been associated with development of acute kidney injury (AKI) during intercurrent illness. Risk factors for AKI in patients prescribed ACEi/ARB therapy are not well described.
Methods We captured the incidence of AKI in patients commencing ACEi/ARB during 2009–2015 using anonymised patient records. Hospital‐coded AKI was defined from hospital episode statistics; biochemical AKI was ascertained from laboratory data. Risk factors for biochemically detected and hospitalised AKI were investigated.
Results Of 61,318 patients prescribed ACEi/ARB, with 132 885 person years (py) follow‐up, there were 1070 hospitalisations with AKI as a diagnosis recorded and a total of 4645 AKI events, including AKI episodes indicated by biochemical KDIGO‐based creatinine change criteria. Incidence of any AKI event was 35.0 per 1000‐py, hospital‐coded AKI was 7.8 per 1000‐py and biochemical AKI was 33.7 per 1000‐py. Independent risk factors in a multivariable model for hospital‐coded AKI events were age, male gender, HF, diabetes, cerebrovascular disease, lower estimated glomerular filtration rate, socioeconomic deprivation, diuretic or non‐steroidal anti‐inflammatory use (all P < 0.001).
Conclusion In patients prescribed ACEi/ARB, the highest risk of AKI is associated with conditions which are considered strong evidence‐based indications for their prescription. Socio‐economic status is an under‐reported risk factor for AKI with these agents. Strategies targeted at prevention of AKI may be of benefit, such as enhanced awareness based on higher risk comorbidities.
Close

Details

Original languageEnglish
Pages (from-to)121-131
Number of pages11
JournalBritish Journal of Clinical Pharmacology
Volume86
Issue number1
Early online date3 Jan 2020
DOIs
Publication statusPublished - 26 Jan 2020

    Research areas

  • Acute kidney injury, Angiotensin, Converting enzyme inhibitor, Angiotensin receptor blocker, Chronic kidney disease, Heart failure

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Changes over time in the management of long-term conditions in primary health-care for adults with intellectual disabilities, and the health-care inequalities gap

    Hughes-McCormack, L., Greenlaw, N., McSkimming, P., McCowan, C., Ross, K., Allan, L., Henderson, A., Melville, C., Morrison, J. & Cooper, S-A., 30 Nov 2020, In: Journal of Applied Research in Intellectual Disabilities. Early View

    Research output: Contribution to journalArticlepeer-review

  2. COVID-19 in Pregnancy in Scotland (COPS): protocol for an observational study using linked Scottish national data

    Stock, S., McAllister, D., Vasileiou, E., Simpson, C. R., Stagg, H. R., Agrawal, U., McCowan, C., Hopkins, L., Donaghy, J., Ritchie, L., Robertson, C., Sheikh, A. & Wood, R., 26 Nov 2020, In: BMJ Open. 10, 11, 11 p., e042813.

    Research output: Contribution to journalArticlepeer-review

  3. Patterns of multimorbidity and their effects on adverse outcomes in rheumatoid arthritis: a study of 5658 UK Biobank participants

    McQueenie, R., Nicholl, B. I., Jani, B. D., Canning, J., Macdonald, S., McCowan, C., Neary, J., Browne, S., Mair, F. S. & Siebert, S., 23 Nov 2020, In: BMJ Open. 10, 11, e038829.

    Research output: Contribution to journalArticlepeer-review

  4. Impact of COVID-19 on accident and emergency attendances and emergency and planned hospital admissions in Scotland: an interrupted time-series analysis

    Mulholland, R. H., Wood, R., Stagg, H. R., Fischbacher, C., Villacampa, J., Simpson, C. R., Vaseleiou, E., McCowan, C., Stock, S. J., Docherty, A. B., Ritchie, L. D., Agrawal, U., Robertson, C., Murray, J. L. K., MacKenzie, F. & Sheikh, A., Nov 2020, In: Journal of the Royal Society of Medicine. 113, 11, p. 444-453

    Research output: Contribution to journalArticlepeer-review

  5. Changes over a decade in psychotropic prescribing for people with intellectual disabilities: prospective cohort study

    Henderson, A., Mcskimming, P., Kinnear, D., McCowan, C., McIntosh, A., Allan, L. & Cooper, S. A., 10 Sep 2020, In: BMJ Open. 10, 9, 9 p., e036862.

    Research output: Contribution to journalArticlepeer-review

Related by journal

  1. Effects of single or combined histamine H-1-receptor and leukotriene CysLT(1)-receptor antagonism on nasal adenosine mono phosphate challenge in persistent allergic rhinitis

    Lee, D. K. C., Jackson, C. M., Soutar, P. C., Fardon, T. C. & Lipworth, B. J., Jun 2004, In: British Journal of Clinical Pharmacology. 57, 6, p. 714-719 6 p.

    Research output: Contribution to journalArticlepeer-review

  2. Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta(2)-receptor genotype

    Sims, E. J., Jackson, C. M. & Lipworth, B. J., Jul 2003, In: British Journal of Clinical Pharmacology. 56, 1, p. 104-111 8 p.

    Research output: Contribution to journalArticlepeer-review

  3. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma

    Lee, D. K. C., Jackson, C. M., Currie, G. P., Cockburn, W. J. & Lipworth, B. J., Nov 2003, In: British Journal of Clinical Pharmacology. 56, 5, p. 494-500 7 p.

    Research output: Contribution to journalArticlepeer-review

  4. Influences on plasma cortisol of different formulations of beclomethasone dipropionate

    Lipworth, B. J. & Jackson, C. M., Oct 2000, In: British Journal of Clinical Pharmacology. 50, 4, p. 381-381 1 p.

    Research output: Contribution to journalLetterpeer-review

ID: 261389937

Top